CRM Therapeutics

CRM Therapeutics is a private Dutch drug-development company focused on oncology. Publicly available evidence indicates the company has been working since 2020 on re-developing vadimezan, a vascular-disrupting small molecule, in combination with a proprietary targeted delivery platform. The company appears to be an early-stage biotech rather than a services business, with limited public disclosure on its broader pipeline, management team, financing, or partnerships. Available corporate registry data places the company in Rotterdam, Netherlands, and indicates it was incorporated in 2017. Based on the accessible evidence, CRM Therapeutics appears to be a small preclinical oncology company centered on targeted delivery-enabled redevelopment of legacy assets.